Shots:
- Biogen has entered into a research collaboration with Dayra Therapeutics to discover & develop oral macrocyclic peptides for priority targets in immunological conditions
- Biogen & Dayra will jointly discover, validate, & optimize oral macrocycle candidates for key immunology targets, after which Biogen will lead development, manufacturing, & potential commercialization
- As per the deal, Dayra will receive a $50M upfront. Biogen will gain an option to acquire the development candidates for a potential additional payment per program, & Dayra will be eligible for further preclinical & clinical development milestone payments per program
Ref: GlobeNewswire | Image: Biogen Partners & Dayra Therapeutics | Press Release
Related News: Samsung Bioepis Enters Asset Purchase Deal with Biogen for Byooviz (Biosimilar, Lucentis) and Opuviz (Biosimilar, Eylea) in the EU
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
